AI-PIA · Clinical care providers
AI Privacy Impact Assessment for Pharmacies
An AI-PIA for a pharmacy examines what an AI tool does with medication-profile, MedsCheck or claims data before it goes live, whether that tool drafts clinical notes, answers the refill line, or forecasts inventory. Stores usually commission this when a PMS vendor rolls out a new AI feature, or when staff start experimenting with a chatbot or note-drafting tool on their own.
Reviewed by the Privacy Horizon team · Last reviewed
What you're protecting
What an AI-PIA has to examine in a pharmacy setting
AI tools touching a dispensary rarely stay confined to one narrow task; the assessment has to trace where medication data actually flows once the tool is in use.
Clinical documentation assistance
Tools that draft or summarize MedsCheck notes handle clinical judgment and patient-specific detail, so the assessment checks what the tool retains and where it processes that text.
Refill-line and chat triage
An AI assistant answering the pharmacy phone line or a website chat needs review for what it can see in the medication profile and whether patients know they are talking to a bot.
Interaction-checking tools
AI that flags potential drug interactions draws on the full medication profile, so the assessment covers accuracy expectations alongside the privacy handling of that data.
Demand-forecasting and inventory tools
Forecasting AI trained on dispensing and claims history can reveal patterns about patient volumes and drug categories that need the same scrutiny as clinical tools.
Regulatory map
Where AI use intersects pharmacy privacy law
No Canadian statute names AI specifically for pharmacies yet, but existing custodian and safeguard duties apply fully to any tool touching PHI.
Custodian accountability doesn't pause for AI
PHIPA's custodian obligations apply to information processed by an AI tool exactly as they would to a human employee, including safeguard and disclosure limits.
Notice obligations for automated interactions
Where a patient is interacting with an AI system rather than a person, notice expectations under PHIPA support being transparent about that fact rather than leaving it ambiguous.
Alberta HIA safeguard duties
Licensed Alberta pharmacies deploying AI tools remain bound by HIA safeguard obligations regardless of whether the processing happens through a human step or an automated one.
PIPEDA for AI touching non-clinical data
A demand-forecasting tool that draws on loyalty or e-commerce data alongside dispensing history brings federal privacy law's accountability principle into the assessment.
What goes wrong
What can go wrong when AI touches medication data
The risks are less about the AI model itself and more about where pharmacy data ends up once a tool is connected.
Medication data leaving the province or country
An AI feature hosted outside Canada can move Rx-file or claims data across borders in ways a store never explicitly agreed to when it enabled the feature.
Patients unaware they're talking to a bot
A refill-line AI that does not identify itself risks patients disclosing more than they would to a known automated system, and risks a transparency complaint.
Retained training data from clinical notes
A note-drafting tool that retains input text for model improvement can turn a single MedsCheck note into a persistent copy outside your PMS's controls.
Over-reliance on interaction-checking output
Staff treating an AI interaction check as a final answer rather than a decision aid introduces clinical risk alongside the privacy questions the assessment covers.
Our ai-pia for pharmacies
What the AI-PIA delivers for a pharmacy
The assessment produces a clear record of how a specific AI tool handles pharmacy data, built for whichever tool your store is evaluating or has already deployed.
Data flow mapping
A clear map of what patient or claims data the AI tool receives, where it is processed, and whether it is retained beyond the immediate task.
Vendor and hosting review
Assessment of the AI vendor's hosting location, data-retention practices and subprocessor arrangements, covering the same ground a PMS vendor review would.
Transparency and notice recommendations
Practical guidance on disclosing AI use to patients where it interacts with them directly, such as a refill-line assistant or chat tool.
Risk findings and mitigations
A prioritized list of privacy risks the tool introduces, with concrete mitigations such as configuration changes, contract terms or usage restrictions.
How the engagement runs
How the AI-PIA runs for your store
Step 1
Identify the AI tool and its purpose
We confirm exactly what the tool does, whether it drafts notes, triages calls, checks interactions or forecasts demand, and what data it needs to do that.
Step 2
Trace the data flow
We map what medication, claims or clinical-service data reaches the tool, where it is processed and stored, and who else can access it.
Step 3
Assess against your obligations
Findings are checked against PHIPA or the applicable provincial statute, along with your existing PHI policies, to identify gaps.
Step 4
Deliver findings and next steps
We report risks and mitigations in plain language, and support the Designated Manager in deciding whether to proceed, adjust configuration, or hold off.
What it costs
What drives AI-PIA cost for a pharmacy
Cost depends on how many AI tools are in scope, how deeply each one touches medication or claims data, and whether the vendor provides documentation readily or requires follow-up. A single note-drafting tool for MedsChecks is a narrower assessment than a banner evaluating a refill-triage chatbot alongside demand-forecasting AI across every store.
Stores on a Virtual Privacy Office retainer often have new-tool assessments included as part of that ongoing service. A short scoping call establishes whether a standalone AI-PIA or the retainer route fits your situation.
Pharmacies: AI-PIA questions, answered
Both are common use cases, and neither is automatically off-limits, but each needs an assessment first. A note-drafting tool needs review of what happens to the clinical text it processes and whether it retains anything, while a refill-triage assistant needs review of what medication data it can see and whether patients are told they are interacting with an automated system rather than a person.
For demand forecasting, the assessment covers what dispensing and claims history the tool trains on and whether that data leaves your systems or the country. For interaction checking, it covers the same data-handling questions plus how confidently staff are expected to rely on the output, since a privacy assessment and a clinical-safety review need to work together on that kind of tool.
Transparency is the safer and more defensible position even where no statute names AI disclosure explicitly for pharmacies yet. PHIPA's general notice expectations support telling patients how their information is being handled, and a patient who later learns an AI system, not a person, triaged their refill request without being told is a foreseeable source of complaint. Simple, upfront disclosure avoids that entirely.
A vendor security review looks at a system broadly: hosting, access controls, contract terms. An AI-PIA goes further into how a specific AI feature processes and potentially retains data for model improvement, and whether patients understand they are interacting with an automated system. Where your PMS vendor adds an AI feature, both reviews typically run together rather than one replacing the other.
This is common and worth surfacing quickly, since an unofficial tool used to summarize a difficult call or draft a note carries the same data-handling risk as a formally deployed one, without the vendor documentation to assess it against. An AI-PIA can start by identifying informal use across the store, then set a clear policy for what is and isn't acceptable going forward.
No, they serve different purposes. The AI-PIA assesses a specific tool's data handling before or during its use, while your core PHI policy sets the ongoing rules staff follow day to day. Once an AI tool passes assessment, its approved use and any conditions typically get folded into the relevant policy so staff have one consistent reference rather than a separate AI document nobody checks.
More for pharmacies
Other services for this niche
- Privacy & security for pharmacies — overview
- Virtual CISO
- Virtual Privacy Officer
- Penetration Testing
- Incident Response Planning
- Privacy & Security Policy Development
- Privacy & Security Training
- Vendor Security Review & Questionnaire Support
- M&A Privacy & Security Due Diligence
- Minimum Viable Privacy Program
About this service
Answers & guides
- Do you need an AI policy before employees use ChatGPT?
- Can you use AI scribes in healthcare while protecting PHI?
- When do you need an AI Privacy Impact Assessment (AI-PIA)?
- AI Scribes in Healthcare: Efficiency Without Exposing PHI
- Conducting an AI PIA in Healthcare: A Practical Walkthrough
- Can Your Team Put Customer or Patient Data Into Generative AI? Drawing the Line
What's Protecting Your Business from the Next Threat?
Don't wait for a breach to expose your vulnerabilities. Let Privacy Horizon secure your data, ensure compliance, and build lasting trust.